Aprea Therapeutics, Inc. (APRE) intrinsic value & 10-year financials
Aprea Therapeutics, Inc. (APRE) has a Graham intrinsic value of $85.75 per share. At $0.58 on Oct 17, 2026, the stock trades 99% below that value. Over the last 10 fiscal years revenue shrank 30.0% a year to $285.8K, with an average return on invested capital of 112.1%.
- Graham intrinsic value
- $85.75
- Share price (Oct 17, 2026)
- $0.58
- Price vs Graham value
- 99% below
- Market cap
- $3.8M
- Revenue (FY2025)
- $285.8K
- Revenue growth (10-yr CAGR)
- -30.0%
- ROIC (10-yr avg)
- 112.1%
- Free cash flow (FY2025)
- —
APRE 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $285.8K | -$12.6M | -$1.93 | — | -4631.1% | -83.4% |
| FY2024 | $1.5M | -$13.0M | -$2.45 | -$13.6M | -953.0% | -79.0% |
| FY2023 | $583.2K | -$14.3M | -$3.95 | -$12.3M | -2652.8% | -72.6% |
| FY2022 | — | -$112.7M | -$68.16 | — | — | -301.8% |
| FY2021 | — | -$37.1M | -$1.74 | — | — | 324.4% |
| FY2020 | — | -$53.5M | -$2.53 | -$41.8M | — | 626.0% |
| FY2019 | — | -$28.1M | -$4.67 | -$26.7M | — | 506.2% |
| FY2018 | — | -$15.5M | — | -$15.3M | — | 35.6% |
| FY2017 | — | -$15.2M | — | — | — | 53.1% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Aprea Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Aprea Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -15.0% ROIC.
Aprea Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Aprea Therapeutics, Inc. is modeled at -30.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $85.75 per share.